These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 18070762

  • 1. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ, Wilton LV, Shakir SA.
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [Abstract] [Full Text] [Related]

  • 2. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV, Wilton LV, Shakir SA.
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [Abstract] [Full Text] [Related]

  • 3. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 5. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
    Marshall V, Wilton L, Shakir S.
    Acta Diabetol; 2006 May; 43(1):6-13. PubMed ID: 16710643
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [Abstract] [Full Text] [Related]

  • 10. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 11. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN, Wilton LV, Shakir SW.
    J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
    [Abstract] [Full Text] [Related]

  • 12. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.
    Perrio MJ, Wilton LV, Shakir SA.
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):969-78. PubMed ID: 17476703
    [Abstract] [Full Text] [Related]

  • 13. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 14. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS.
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [Abstract] [Full Text] [Related]

  • 15. Long-term pharmacotherapy for obesity.
    Klein S.
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [Abstract] [Full Text] [Related]

  • 16. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction.
    Maclennan KM, Boshier A, Wilton LV, Shakir SA.
    BJU Int; 2006 Jul; 98(1):125-31. PubMed ID: 16831156
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Jul; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 18. Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
    Hill GR, Ashton J, Harrison-Woolrych M.
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1217-26. PubMed ID: 17661435
    [Abstract] [Full Text] [Related]

  • 19. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2003 Nov; (4):CD004094. PubMed ID: 14584004
    [Abstract] [Full Text] [Related]

  • 20. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y, Layton D, Fogg C, Shakir SA.
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.